Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02774590 · ClinicalTrials.gov registry record · Phase 1

Timolol for the Treatment of Acne and Rosacea

A Phase 1 study of Acne Vulgaris and Rosacea, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT02774590: Completed Phase 1 study of Acne Vulgaris and Rosacea, sponsored by Johns Hopkins University.

NCT02774590 is a Phase 1 study of Acne Vulgaris and Rosacea that has completed, run by Johns Hopkins University. The registered enrollment target is 8 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02774590, a Phase 1 study of Acne Vulgaris and Rosacea, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This research is being done to determine the safety and tolerability of timolol in the treatment of acne and rosacea. The investigators will also look for specific biomolecular changes in acne or rosacea skin when it is exposed to timolol. Timolol is approved by the Food and Drug Administration (FDA) for the treatment of glaucoma. In dermatology, it has been used as a treatment to decrease the size of vascular (blood vessel) malformations in infant skin. Timolol is not approved for use in acne or rosacea and its use in this study is investigational. Many people with rosacea have telangiectasias which are small, red dilated blood vessels on the skin. They also suffer from flushing and acne-like lesions. Better treatments than those currently available are desired. Acne vulgaris, or acne, is another chronic inflammatory and very common skin disease that affects about 8 out of 10 young adults and adolescents. Signs of acne include papules and blackheads that are often called primary lesions because they represent an active form of the disease. There are also secondary lesions that can form later; they are known as acne scars

Primary Outcome

To determine the safety and tolerability of Timolol in the treatment of acne and rosacea

Conditions Studied

Acne Vulgaris Rosacea

Interventions

  • DRUG Timolol

Study Locations (1)

Maryland

  • Johns Hopkins Dermatology Department - Baltimore

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2016-03
Est. Completion 2021-03
Phase Phase 1
Johns Hopkins University

1,448 total trials

What the finished NCT02774590 record still lists

NCT02774590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Timolol is the first listed.

NCT02774590 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02774590 about?

NCT02774590 is a clinical study titled "Timolol for the Treatment of Acne and Rosacea". This research is being done to determine the safety and tolerability of timolol in the treatment of acne and rosacea. The investigators will also look for specific biomolecular changes in acne or rosacea skin when it is exposed to timolol. Timolol is approved by the Food and Drug Administration (FD...

What is the current status of trial NCT02774590?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-03. Estimated completion is 2021-03.

What conditions does trial NCT02774590 study?

This clinical trial studies the following conditions: Acne Vulgaris, Rosacea.

What interventions are being tested in trial NCT02774590?

The interventions under investigation include: Timolol (DRUG).

Who is sponsoring clinical trial NCT02774590?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02774590 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02774590's enrollment target sits among peer trials

8 68th of 67 the lowest of 67 other Acne Vulgaris trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02774590, the US trial registry maintained by the National Library of Medicine. NCT02774590 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.